Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.01. | France's Vetoquinol drops on profit taking | - | Reuters | ||
24.01. | Vetoquinol: Annual Sales 2023: €529 Million | 327 | Business Wire | Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)
Regulatory News:
Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), said: "In an animal... ► Artikel lesen | |
03.01. | Vetoquinol: 2024 Calendar of Financial Communication | 343 | Business Wire | Regulatory News:
Vetoquinol (Paris:VETO) published its calendar of financial communication for 2024.
January 24, 2024: 2023 Annual revenues (after market)
March 20, 2024: 2023 Annual... ► Artikel lesen | |
26.10.23 | Vetoquinol: Sales 3rd Quarter 2023 | 339 | Business Wire | Q3 Sales: €136m (+5.1% at constant exchange rates)
Q3 Essentials Sales: €81m (+12.2% at constant exchange rates)
Regulatory News:
Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO)... ► Artikel lesen | |
09.10.23 | Vetoquinol: Announcement of the Availability of the Half-Year Financial Report to June 30, 2023 | 513 | Business Wire | Regulatory News:
Vetoquinol (Paris:VETO) announced today that it has made available to the public and filed with the Autorité des marchés financiers its Half-Year Financial Report to June 30, 2023.... ► Artikel lesen | |
13.09.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 342 | Business Wire | Sustainable development, an integral part of Vetoquinol
Regulatory News:
Vetoquinol's (Paris:VETO) corporate vision underlines its ambition for its entire ecosystem. This vision creates a dynamic... ► Artikel lesen | |
07.09.23 | Vetoquinol: 2023 Half-Year Results | 459 | Business Wire | Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m
Regulatory... ► Artikel lesen | |
27.07.23 | Vetoquinol, Virbac, and FRONTLINE Among Winners at the 2023 - 2024 World Branding Awards Animalis Edition in Vienna | 583 | Business Wire | The third instalment of the Animalis Edition at the 2023 2024 World Branding Awards welcomed pet and animal brands from around the world, celebrating their achievements as National, Regional, and... ► Artikel lesen | |
19.06.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 335 | Business Wire | Recalling a memorable anniversary day
Regulatory News:
The Vetoquinol (Paris:VETO) saga started 90 years ago in the back office of the Frechin family pharmacy in Lure, Franche Comté (East of... ► Artikel lesen | |
12.06.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 412 | Business Wire | Growth driven by innovation 90 years of innovation
Regulatory News:
Vetoquinol (Paris:VETO):
Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's... ► Artikel lesen | |
02.06.23 | Dividendenbekanntmachungen (02.06.2023) | 7.274 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,65 EUR ANALOG DEVICES INC US0326541051 0,86 USD 0,7992 EUR ANHUI CONCH CEMENT CO LTD CNE1000001W2 1... ► Artikel lesen | |
25.05.23 | 3rd Generation Appointed Chairman of the Board of Directors of Vetoquinol SA | 420 | Business Wire | Regulatory News:
The Combined General Meeting of Vetoquinol (Paris:VETO) shareholders was held on Thursday 25 May 2023 at the laboratory's head office in Lure (Franche-Comté), chaired by Mr. Etienne... ► Artikel lesen | |
02.05.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 467 | Business Wire | Essential products for the most common needs
Regulatory News:
Vetoquinol (Paris:VETO):
A strategy to meet the needs of its customers.
Vetoquinol is an independent, international animal... ► Artikel lesen | |
24.04.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 334 | Business Wire | The animal health company is firmly established in the world's Top 10.
Regulatory News:
Vetoquinol (Paris:VETO):
A family-owned and independent company
Vetoquinol has managed to preserve... ► Artikel lesen | |
19.04.23 | Vetoquinol: Q1 2023 Sales: €145M | 338 | Business Wire | Q1 2023 Essentials Sales: €87M
Regulatory News:
Matthieu Frechin, Chief Executive Officer of Vetoquinol (Paris:VETO), said: "While we remain aware of the macro-economic uncertainty and the... ► Artikel lesen | |
13.04.23 | Vetoquinol: Availability of the 2022 Universal Registration Document | 465 | Business Wire | Regulatory News:
On 13 April 2023, Vetoquinol (Paris:VETO) filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).... ► Artikel lesen | |
27.03.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 501 | Business Wire | The key steps of a visionary strategy
Regulatory News:
Vetoquinol (Paris:VETO):
Strategic insights
From the very beginning, Vetoquinol's strategy has been linked to the history of the... ► Artikel lesen | |
23.03.23 | Vetoquinol SA: Vetoquinol: 2022 Annual Results | 537 | Business Wire | Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income Group share: €48m (8.9% of... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,215 | -0,08 % | BERENBERG stuft BAYER AG auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Bayer von 34 auf 30 Euro gesenkt und die Einstufung auf "Hold" belassen. Die Erwartungen an den Agrarchemie- und Pharmakonzern... ► Artikel lesen | |
SANOFI | 87,99 | +0,07 % | ANALYSE-FLASH: Stifel hebt Sanofi auf 'Buy' und Ziel auf 109 Euro | FRANKFURT (dpa-AFX Broker) - Die Investmentbank Stifel hat Sanofi von "Hold" auf "Buy" hochgestuft und das Kursziel von 95 auf 109 Euro angehoben. Bis 2027 winke den Franzosen ein zweistelliges Wachstum... ► Artikel lesen | |
BRISTOL-MYERS SQUIBB | 47,600 | -0,31 % | Bristol Myers, Moderna und Roche ziehen Anti Virus-Index auf Jahreshoch | ||
DERMAPHARM | 33,520 | -6,94 % | Ausgelaufene Covid-Impfstoffproduktion belastet Dermapharm | GRÜNWALD (dpa-AFX) - Der Arzneimittelhersteller Dermapharm hat im vergangenen Jahr trotz Wachstum im Tagesgeschäft weniger verdient. Für 2024 stelle man sich nun zwar auf ein Umsatzplus ein, beim operativen... ► Artikel lesen | |
DOCMORRIS | 84,23 | +0,06 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 3 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0039542854 MCH... ► Artikel lesen | |
INCYTE | 53,32 | +0,98 % | Incyte's JAK inhibitor cream Opzelura shows promise in hidradenitis suppurativa | ||
GREEN THUMB INDUSTRIES | 12,440 | +0,89 % | Green Thumb Industries: Aktie muss nachsetzen | Anzeige / WerbungLetztendlich blieben aber positive Impulse auf den Aktienkurs aus. Dabei wären diese dringend notwendig.Green Thumb Industries veröffentlichte am gestrigen Mittwoch (28. Februar) die... ► Artikel lesen | |
TRYP THERAPEUTICS | 0,010 | -20,00 % | Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order | KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the Company's securityholders overwhelmingly approved... ► Artikel lesen | |
OPKO HEALTH | 0,804 | +0,02 % | OPKO Health, Inc.: AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV | • Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies... ► Artikel lesen | |
BACHEM | 84,18 | -0,91 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 4 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0305285295 VARIA... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 0,980 | +0,41 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
COSMO PHARMACEUTICALS | 68,50 | -4,20 % | Cosmo Pharmaceuticals N.V.: Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024 | Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announced today that it will publish its Full-Year 2023 results on Wednesday... ► Artikel lesen | |
ORION | 35,630 | +1,05 % | Orion Oyj: Managers' transactions - Satu Ahomäki | ORION CORPORATION MANAGERS' TRANSACTIONS 4 MARCH 2024 at 13.00 EET
Orion Corporation: Managers' transactions - Satu Ahomäki
Orion Corporation has received the following disclosure under... ► Artikel lesen | |
OXFORD BIOMEDICA | 2,180 | +4,81 % | Oxford BioMedica plc: Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results | Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024... ► Artikel lesen | |
CITIUS PHARMACEUTICALS | 0,641 | -4,40 % | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma | FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024
CRANFORD, N.J., March 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq:... ► Artikel lesen |